ABBV Jan 2025 110.000 put
| Previous close | 2.8600 |
| Open | 2.8600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 110.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.8600 - 2.8600 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.73k |
- Yahoo Finance Video
FTC warns pharma companies on excessive drug patenting
The Federal Trade Commission (FTC) issued warning letters to several pharmaceutical companies, including AbbVie (ABBV) AstraZeneca (AZN), and Teva (TEVA), over excessive patenting of medications as Medicare negotiates drug costs with the pharma industry. Yahoo Finance Health Reporter Anjalee Khemlani explains the Biden administration's ideas to license patents to lower drug costs for patients. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
- Yahoo Finance Video
AbbVie acquiring Cerevel Therapeutics in $8.7B deal
AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Motley Fool3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows
Buying these shares can provide you with some excellent recurring income while also diversifying your portfolio.
